← Leaderboards
David H Viskochil
University Of Utah
$1,815,146
Attributed
$1,815,146
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $421.1K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,815,146 · 11
By mechanism
R01$1,574,324 · 1
M01$240,822 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- David Andrew Stevenson$880,470
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHereditary DiseaseHuman SubjectNeoplasm /Cancer GeneticsNeurofibromatosisGene Deletion MutationGene ExpressionTumor Suppressor GenesLoss Of HeterozygosityAllelesAntibodyMessenger RnaBone ResorptionBone HealthFundingFutureGrantAreaBone DensityChildClinical ManagementDefectDeformityCohort
Grant awards (19)
Spinal abnormalities in neurofibomatosis type 1$290,668
R01 · FY2010 · NS · contact PI
Spinal abnormalities in neurofibomatosis type 1$286,873
R01 · FY2009 · NS · contact PI
Spinal abnormalities in neurofibomatosis type 1$277,477
R01 · FY2008 · NS · contact PI
CLINICAL GENETICS RESEARCH PROGRAM$12,035
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: MPS II PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY$688
M01 · FY2008 · RR · contact PI
Spinal abnormalities in neurofibomatosis type 1$340,069
R01 · FY2007 · NS · contact PI
CLINICAL GENETICS RESEARCH PROGRAM$76,658
M01 · FY2007 · RR · contact PI
MPS II PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY$4,381
M01 · FY2007 · RR · contact PI
Spinal abnormalities in neurofibomatosis type 1$379,237
R01 · FY2006 · NS · contact PI
MPS II PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY$16,655
M01 · FY2006 · RR · contact PI
RECOMBINANT HUMAN ALPHA-L IDURONIDASE IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS I$61,244
M01 · FY2005 · RR
SKELETAL PHENOTYPING AND MUTATION SCREENING IN NEUROFIBROMATOSIS$6,502
M01 · FY2005 · RR
Extension trial for enzyme replacement therapy in MPS 1$58,537
M01 · FY2004 · RR
Somatic mutation analysis of neurofibromatosis Type 1$874
M01 · FY2004 · RR
SOMATIC MUTATION ANALYSIS OF NEUROFIBROMATOSIS TYPE I$0
M01 · FY2002 · RR
SOMATIC MUTATION ANALYSIS OF NEUROFIBROMATOSIS TYPE I$1,624
M01 · FY2001 · RR
SOMATIC MUTATION ANALYSIS OF NEUROFIBROMATOSIS TYPE I$0
M01 · FY2001 · RR
SOMATIC MUTATION ANALYSIS OF NEUROFIBROMATOSIS TYPE I$0
M01 · FY2001 · RR
SOMATIC MUTATION ANALYSIS OF NEUROFIBROMATOSIS TYPE I$1,624
M01 · FY2000 · RR